Study: NCT01348100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone crystalline formulation
Description: Iloperidone was formulated as 100 µm crystals for IM depot injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone crystalline formulation
Description: Iloperidone was formulated as 100 µm crystals for IM depot injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone crystalline formulation
Description: Iloperidone was formulated as 100 µm crystals for IM depot injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone microparticle formulation
Description: Iloperidone was formulated as microparticles for IM depot injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone microparticle formulation
Description: Iloperidone was formulated as microparticles for IM depot injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone microparticle formulation
Description: Iloperidone was formulated as microparticles for IM depot injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone microparticle formulation
Description: Iloperidone was formulated as microparticles for IM depot injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral iloperidone
Description: Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral iloperidone
Description: Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral iloperidone
Description: Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral iloperidone
Description: Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral iloperidone
Description: Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral iloperidone
Description: Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral iloperidone
Description: Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.